Effect of Valsalva on Brain Function in HIFU Hepatic Tumor Ablation and Countermeasure Study

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057054

Enrollment

Unknown

Registered

2022-02-27

Start date

2022-03-07

Completion date

Unknown

Last updated

2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic tumor

Interventions

Experimental group:Valsalva

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients >=18 years old and <=80 years old; 2. HIFU tumor patients receiving HIFU ablation and requiring Valsalva procedure; 3. Patients with ASA grade I-III; 4. Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with liver and kidney insufficiency, stroke, cerebral hemorrhage, infectious diseases, and immune system diseases; 2. Patients with preoperative mental disorders such as delirium and cognitive dysfunction; 3. Patients with serious mental illness.

Design outcomes

Primary

Measure	Time frame
Burst suppression;	—

Secondary

Measure	Time frame
Blood pressure;Heart rate;Oxygen saturation;Patient status index, PSIPsi;	—

Countries

China

Contacts

Public ContactShu Shiyu

The Second Affiliated Hospital of Chongqing Medical University

shushiyu@hotmail.com+86 18917785284

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026